Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Black cab driver who fled a fatal midnight hitHeartbroken Zoe Ball pays tribute to late partner Billy Yates seven years since his passingZibanejad has 2 goals and 1 assist, Panarin scores as Rangers beat Hurricanes 4DEAR JANE: My wife has ditched her razor for goodJavier Assad pitches 6 innings as Cubs blank Brewers 59 months of war will wipe out 44 years of human development in Gaza: UN reportKremer pitches 6 shutout innings and Santander hits a grand slam to help Orioles sweep RedsOne year on, a lowArozarena hits tying homer off Díaz in 9th, DeLuca's 2London mayor race: Labour's Sadiq Khan to secure record third term
2.5438s , 6498.0234375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Cultural Currents news portal